Deutsche Bank downgraded Argenx (ARGX) to Hold from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s Phase 3 Study on Efgartigimod: A Potential Game-Changer in Autoimmune Treatment
- Argenx Advances in Systemic Sclerosis Treatment with Efgartigimod PH20 SC Study
- Argenx’s Phase 3 Study on Empasiprubart: A Potential Game-Changer for MMN Treatment?
- Argenx’s CIDP Study: Transitioning from IVIg to Efgartigimod PH20 SC
- Argenx Advances Pediatric gMG Treatment with Efgartigimod Study